CVS: Rerating – Downgrade From Strong Buy To Hold (NYSE:CVS)

[ad_1]

Boston Area Continues Covid-19 Testing At Sites Around City

Maddie Meyer

Background

In late July 2023, I published an article with a strong buy rating on CVS Health (NYSE:CVS), which you can access here. At the time, CVS was firmly in the market’s “doghouse”: the stock was 52% off its

[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *